Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats

Molecular Medicine

Volumn 14, Issue 7-8, 2008, Pages 395-402

  Xing, Shan Shan ^b   Tan, Hong Wei ^b   Bi, Xiu Ping ^b   Zhong, Ming ^b   Zhang, Yun ^b   Zhang, Wei ^a  

^a SHANDONG UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FELODIPINE; FRUCTOSE; INSULIN; INTERLEUKIN 18; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY; HEART; HEART LEFT VENTRICLE; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VASCULAR FIBROSIS;

ANIMAL FEED; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; FELODIPINE; FIBROSIS; FRUCTOSE; HEART; INTERLEUKIN-18; MALE; MYOCARDIUM; RATS; RATS, INBRED WKY;

EID: 48149112149     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2008-00024.Xing     Document Type: Article

References (52)

1. Bonora E et al. (2003) Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care. 26:1251-7.
2. Reilly MP et al. (2004) Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 110:803-9.
3. Reaven GM. (1988) Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 37:1595-607.
4. Meigs JB. (2000) Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am. J. Epidemiol. 152:908-12.
5. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. (2000) Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol. 152:897-907.
6. Zaman AK et al. (2004) Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J. Mol. Cell. Cardiol. 37:525-35.
7. Reaven GM. (1988) Role of insulin resistance in human disease. Diabetes. 37:1595-606.
8. Haffner S, Taegtmeyer H. (2003) Epidemic obesity and the metabolic syndrome. Circulation. 108:1541-5.
9. Murakami H, Urabe K, Nishimura M. (1998) Inappropriate microvascular constriction produced transient ST-segment elevation in patients with syndrome X. J. Am. Coll. Cardiol. 32:1287-94.
10. Pickup JC, Mattock MB, Chusney GD, Burt D. (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and IL-6 with metabolic syndrome X. Diabetologia. 40:1286-92.
11. Pickup JC. (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 27:813-23.
12. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. (2003) Atherothrombosis, inflammation, and diabetes. J. Am. Coll. Cardiol. 41:1071-7.
13. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. (1998) Interleukin-18: a novel cytokine that augments both acquired and innate immunity. Adv. Immunol. 70:281-312.
14. Gracie JA, Robertson SE, McInnes IB. (2003) Interleukin-18. J. Leukoc. Biol. 73:213-24.
15. Mallat Z et al. (2001) Expression of IL-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 104:1598-603.
16. Blankenberg S et al. (2002) AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 106:24-30.
17. Blankenberg S et al. (2003) PRIME Study Group. IL-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 108:2453-9.
18. Esposito K. et al. (2002) Weight loss reduces IL-18 levels in obese women. J. Clin. Endocrinol. Metab. 87:3864-6.
19. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL. (2004) Serum IL-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J. Clin. Endocrinol. Metab. 89:806-11.
20. Esposito K et al. (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 106:2067-72.
21. Esposito K et al. (2003) Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 26:1647.
22. Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. (2003) Relationships of plasma IL-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care. 26:2622-7.
23. Stetler-Stevenson WG. (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103:1237-41.
24. El Messal M et al. (2006) Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin. Chim. Acta. 366:185-9.
25. Miatello R et al. (2005) Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens. 18:864-70.
26. Huang BW, Chiang MT, Yao HT, Chiang W. (2004) The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. Diabetes Obes. Metab. 6:120-6.
27. Hishikawa K, Lüscher TF. (1998) Felodipine inhibits free-radical production by cytokines and glucose in human smooth muscle cells. Hypertension. 32:1011-5.
28. Rödler S, Roth M, Nauck M, Tamm M, Block LH. (1995) Ca(2+)-channel blockers modulate the expression of interleukin-6 and interleukin-8 genes in human vascular smooth muscle cells. J. Mol. Cell. Cardiol. 27:2295-302.
29. Bunag RD. (1973) Validation in awake rats of a tail-cuff method for measuring systolic pressure. J. Appl. Physiol. 34:279-82.
30. Bunag RD. (1994) Blood pressure measurement in rats. In: Garten D, De Jong W. Experimental and genetic models of hypertension. Handbook of hypertension, vol 16. Amsterdam: Elsevier, pp:1-17.
31. Matthews DR et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412-9.
32. Masson P. (1992) Trichrome stainings and their preliminary technique. J. Tech. Methods. 2:75-90.
33. Livak KJ, Schmittgen TD. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method. Methods. 25:402-8.
34. Basciano H, Federico L, Adeli K. (2005) Fructose, insulin resistance, and metabolic dyslipidemia. Nutr. Metab. 2:5.
35. Frohlich M et al. (2000) Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 23:1835-9.
36. Festa A et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 102:42-7.
37. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. (2000) Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol. 152:897-907.
38. Hak AE et al. (2001) Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J. Clin. Endocrinol. Metabol. 86:4398-405.
39. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. (2005) Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 25:1268-73.
40. Zirlik A et al. (2007) Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler. Thromb. Vasc. Biol. 27:2043-9.
41. Greenberg AS, McDaniel ML. (2002) Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur. J. Clin. Invest. 32:24-34.
42. McLaughlin T et al. (2002) Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 106:2908-12.
43. Reddy VS et al. (2008) Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. J. Cell. Physiol. 215:697-707.
44. Gerdes N et al. (2002) Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. 195:245-57.
45. Abaci A et al. (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 99:2239-42.
46. Schaper W, Buschmann I. (1999) Collateral circulation and diabetes. Circulation. 99:2224-6.
47. Zaman AK et al. (2001) Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation. 103:3123-8.
48. Matsumori A, Nunokawa Y, Sasayama S. (2000) Nifedipine inhibits activation of transcription factor NF-kappaB. Life Sci. 67:2655-61.
49. Iwasaki Y et al. (2004) Nilvadipine inhibits nuclear factor-kappaB-dependent transcription in hepatic cells. Clin. Chim. Acta. 350:151-7.
50. Matsubara M, Hasegawa K. (2004) Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells. Eur. J. Pharmacol. 498:303-14.
51. Ding Y, Vaziri ND. (1998) Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension. 32:718-23.
52. Jesmin S et al. (2006) Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats. Am. J. Physiol. Heart Circ. Physiol. 290:2146-54.